Genetic Technologies Limited Announces Updated Investor Presentation
09 8월 2023 - 9:00PM
Genetic Technologies Limited (NASDAQ: GENE, ASX: GTG, “Company”), a
global leader in genomics-based tests in health, wellness and
serious disease, is pleased to provide an update on the company’s
activities via the latest investor presentation attached.
Enquiries
Investor RelationsAdrian MulcahyAutomic
MarketsM: +61 438 630 411E: adrian.mulcahy@automicgroup.com.au
About Genetic Technologies
Limited
Genetic Technologies Limited (ASX: GTG; Nasdaq:
GENE) is a diversified molecular diagnostics company. A global
leader in genomics-based tests in health, wellness and serious
disease through its geneType and EasyDNA brands. GTG offers cancer
predictive testing and assessment tools to help physicians to
improve health outcomes for people around the world. The company
has a proprietary risk stratification platform that has been
developed over the past decade and integrates clinical and genetic
risk to deliver actionable outcomes to physicians and individuals.
Leading the world in risk prediction in oncology, cardiovascular
and metabolic diseases, Genetic Technologies continues to develop
risk assessment products. For more information, please visit
www.genetype.com
Forward Looking Statements
This announcement may contain forward-looking
statements about the Company's expectations, beliefs or intentions
regarding, among other things, statements regarding the expected
use of proceeds. In addition, from time to time, the Company or its
representatives have made or may make forward-looking statements,
orally or in writing. Forward-looking statements can be identified
by the use of forward-looking words such as "believe," "expect,"
"intend," "plan," "may," "should" or "anticipate" or their
negatives or other variations of these words or other comparable
words or by the fact that these statements do not relate strictly
to historical or current matters. These forward-looking statements
may be included in, but are not limited to, various filings made by
the Company with the U.S. Securities and Exchange Commission, press
releases or oral statements made by or with the approval of one of
the Company's authorized executive officers. Forward-looking
statements relate to anticipated or expected events, activities,
trends or results as of the date they are made. As forward-looking
statements relate to matters that have not yet occurred, these
statements are inherently subject to risks and uncertainties that
could cause the Company's actual results to differ materially from
any future results expressed or implied by the forward-looking
statements. Many factors could cause the Company's actual
activities or results to differ materially from the activities and
results anticipated in such forward-looking statements as detailed
in the Company's filings with the Securities and Exchange
Commission and in its periodic filings with the ASX in Australia
and the risks and risk factors included therein. In addition, the
Company operates in an industry sector where securities values are
highly volatile and may be influenced by economic and other factors
beyond its control. The Company does not undertake any obligation
to publicly update these forward-looking statements, whether as a
result of new information, future events or otherwise, except as
required by law.
A PDF accompanying this announcement is
available
at http://ml.globenewswire.com/Resource/Download/476c24d4-b29a-4f91-9a2a-356b969cb1b8
Genetic Technologies (NASDAQ:GENE)
과거 데이터 주식 차트
부터 12월(12) 2024 으로 1월(1) 2025
Genetic Technologies (NASDAQ:GENE)
과거 데이터 주식 차트
부터 1월(1) 2024 으로 1월(1) 2025